Pivotal bioVenture Partners Investment Advisor Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ZBIO
Zenas BioPharma
ZBIO
|
+$11.7M |
| 2 |
BIOA
BioAge Labs
BIOA
|
+$10.6M |
| 3 |
Arcutis Biotherapeutics
ARQT
|
+$784K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vaxcyte
PCVX
|
+$13.8M |
| 2 |
Aligos Therapeutics
ALGS
|
+$260K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
Similar funds
Pivotal bioVenture Partners Investment Advisor's Q3 2024 Portfolio in Review
As of Q3 2024, Pivotal bioVenture Partners Investment Advisor held 12 positions worth $168M, up 30% from $130M the previous quarter. Its ten largest holdings account for 99% of the portfolio.
Pivotal bioVenture Partners Investment Advisor deployed $8.96M of net new capital in Q3 2024, opening 2 new positions and adding to 1 existing holding. Its largest new stake was Zenas BioPharma: 650,695 shares worth $11M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Vaxcyte, an estimated $13.8M trimmed.
- Pivotal bioVenture Partners Investment Advisor's largest Q3 2024 buy was Zenas BioPharma: 650,695 shares worth $11M.
- Pivotal bioVenture Partners Investment Advisor added most to Arcutis Biotherapeutics in Q3 2024, an estimated $784K increase.
- Pivotal bioVenture Partners Investment Advisor's biggest Q3 2024 reduction was Vaxcyte, cutting an estimated $13.8M.
- Pivotal bioVenture Partners Investment Advisor fully exited Aligos Therapeutics in Q3 2024, selling an estimated $260K.
- Pivotal bioVenture Partners Investment Advisor's ten largest holdings make up 99% of its $168M portfolio in Q3 2024.
- Pivotal bioVenture Partners Investment Advisor opened 2 new positions and closed 1 in Q3 2024.
- Pivotal bioVenture Partners Investment Advisor's portfolio value rose 30% quarter-over-quarter to $168M.
Based on Pivotal bioVenture Partners Investment Advisor's 13F filing for Q3 2024, filed 13 Nov 2024.